Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Summary

The purpose of this pilot study is to assess repository corticotropin injection (RCI) in the form of H.P. Acthar Gel in patients with severe keratoconjunctivitis sicca (KCS, or dry eye disease). This pilot study is a non-randomized, open-label, interventional study to assess the efficacy and timeline of RCI for the treatment of severe KCS recalcitrant to conventional therapy. The purpose is to acquire preliminary data to support and guide the design of a future, double-masked, randomized, controlled clinical trial.

Timeline

Start

2018-11-01

Primary completion

2018-11-01

Completion

2018-11-01

Outcome

Outcome not reported

Stopped: “Change of direction”

Drugs

Indications